Tuberculosis treatment active vs Tuberculosis treatment latent
How to tell Tuberculosis treatment active and Tuberculosis treatment latent apart when a board question makes them look alike.
Step 2 CK pairs are in open beta while clinical review finishes. Spot an issue? Tell us.
Evidence of active pulmonary disease on symptoms plus positive sputum testing separates active TB treatment from latent TB treatment.
Side by side
Symptomatic or microbiologically confirmed pulmonary tuberculosis requires multidrug active-disease therapy and airborne isolation.
Positive TB infection testing without symptoms or radiographic active disease indicates latent TB treatment to prevent progression.
Replicating Mycobacterium tuberculosis in active disease requires multidrug bactericidal and sterilizing therapy to prevent resistance.
Latent TB reflects immune containment of nonreplicating bacilli, treated with preventive regimens to reduce reactivation risk.
Active TB is supported by positive sputum NAAT or acid-fast smear with confirmatory culture, compatible chest imaging such as upper-lobe cavitary infiltrates, and clinical symptoms including cough for more than 3 weeks, weight loss, night sweats, or fever.
Latent TB has positive IGRA or tuberculin skin test with no symptoms, normal or stable nonactive chest radiograph, and negative sputum studies when evaluated for active disease exclusion.
The trap
A positive IGRA can lead to under-treatment if symptoms and imaging already suggest active disease. The resolving clue is microbiologic and clinical evidence of ongoing infection, which requires full multidrug treatment and isolation rather than latent-only monotherapy.
The repair move
Next best step: place the patient in airborne isolation and start active TB regimen with isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, then continue isoniazid plus rifampin for 18 weeks with pyridoxine supplementation and susceptibility-guided adjustment; for latent TB after active disease exclusion, use a preventive regimen such as isoniazid 300 mg daily for 6 to 9 months or rifampin 600 mg daily for 4 months.
Try a free question
CoreA patient has chronic cough, fevers, upper-lobe cavitary infiltrate, and positive sputum NAAT for Mycobacterium tuberculosis. What is the next best step in management?
Show answer and explanation
Answer: B. Start RIPE therapy and airborne isolation. Confirmed active pulmonary TB requires immediate multidrug therapy plus airborne isolation.
Why the other choices are tempting
- A. Wrong because monotherapy is inadequate and dangerous for active disease due to resistance risk.
- C. Wrong because delayed treatment worsens transmission and disease progression risk.
- D. Wrong because macrolide monotherapy does not treat active pulmonary TB effectively.
- E. Wrong because active pulmonary TB requires airborne precautions, not routine discharge without control measures.
Flashcards
Tap a card to flip it.
What treatment intensity is required when sputum testing confirms active pulmonary TB?
Use multidrug active-disease therapy, typically RIPE induction followed by continuation therapy based on susceptibility.
What testing profile supports latent TB rather than active TB?
Positive IGRA or TST with no symptoms, no active imaging findings, and no microbiologic evidence of active infection.
Quick answers
What is the fastest way to tell Tuberculosis treatment active from Tuberculosis treatment latent?
Evidence of active pulmonary disease on symptoms plus positive sputum testing separates active TB treatment from latent TB treatment.
What is the key clue for Tuberculosis treatment active?
Symptomatic or microbiologically confirmed pulmonary tuberculosis requires multidrug active-disease therapy and airborne isolation.
What is the key clue for Tuberculosis treatment latent?
Positive TB infection testing without symptoms or radiographic active disease indicates latent TB treatment to prevent progression.
What is the common trap with Tuberculosis treatment active vs Tuberculosis treatment latent?
A positive IGRA can lead to under-treatment if symptoms and imaging already suggest active disease. The resolving clue is microbiologic and clinical evidence of ongoing infection, which requires full multidrug treatment and isolation rather than latent-only monotherapy.